Oruka Therapeutics (ORKA) Other Non-Current Liabilities (2023 - 2025)
Oruka Therapeutics' quarterly Other Non-Current Liabilities came in at $9.7 million in Q3 2025, up 26.08% year-on-year from $7.7 million in Q3 2024, and up 213.5% quarter-over-quarter from $3.1 million in Q2 2025.
Oruka Therapeutics has reported Other Non-Current Liabilities for 3 years, with the latest figure at $9.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 9.68 Mn |
| Jun 30, 2025 | 3.09 Mn |
| Mar 31, 2025 | 1.42 Mn |
| Sep 30, 2024 | 7.68 Mn |
| Sep 30, 2023 | 432,000.00 |
| Jun 30, 2023 | 432,000.00 |